Bristol-Myers Says Nimbus Wants To Keep New Drug For Itself

By Bryan Koenig ( September 16, 2021, 11:13 PM EDT) -- Bristol-Myers Squibb Co. and its subsidiary Celgene Corp. hit back against a biotechnology company's bid to avoid selling them a psoriasis drug the startup is developing, complaining that Nimbus Therapeutics LLC's lawsuit seeking to escape its promise to shed the anti-inflammatory is a backdoor way of attacking the pharma giant's completed acquisition of Celgene. . . .

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Law firms are actively looking for ways to incorporate artificial intelligence into their workflow as it becomes ever more common. More than half of surveyed attorneys at U.S. law firms use generative AI for some purpose — up significantly from less than a third of attorneys who participated in the Law360 Pulse AI Survey last year.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!